Site icon pharmaceutical daily

Epilepsy Pipeline Review 2020: Therapeutic Analysis Report Featuring 140+ Companies & Drug Profiles – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Epilepsy – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epilepsy (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 1, 4, 28, 29, 5, 113, 24 and 4 respectively. Similarly, the Universities portfolio in Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 22 and 3 molecules, respectively.

Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction

Epilepsy – Therapeutics Assessment

Epilepsy – Companies Involved in Therapeutics Development

Epilepsy – Drug Profiles

Epilepsy – Dormant Projects

(Read more…)

Appendix

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/3oqs8q

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version